PepGen

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
BioSpace
Tue, 02/20/24 - 05:49 pm
PepGen
oligonucleotides
PGN-EDODM1
myotonic muscular dystrophy
PepGen cleared by FDA to begin study of muscular dystrophy drug
BioPharma Dive
Thu, 10/12/23 - 05:20 pm
PepGen
FDA
myotonic muscular dystrophy
Awaiting FDA hold letter, PepGen accepts 2nd oligonucleotide is no closer to clinic
Fierce Biotech
Wed, 06/14/23 - 11:30 am
PepGen
oligonucleotide
FDA
myotonic muscular dystrophy
PGN-EDODM1
Three Influential Women in Biopharma Explain How to Break the Executive Barrier
BioSpace
Thu, 11/17/22 - 11:30 pm
women
women executives
AltruBio
PepGen
X4 Pharmaceuticals
Pepgen aims to overtake Sarepta
EP Vantage
Wed, 09/28/22 - 11:00 am
Sarepta Therapeutics
PepGen
Duchenne Muscular Dystrophy
PGN-ED051
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
Fierce Biotech
Fri, 05/6/22 - 10:55 am
PepGen
IPOs
Sarepta Therapeutics
Duchenne Muscular Dystrophy